• 15897 Citations
  • 65 Scopus h-Index
1982 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Jan Craig Buckner is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 26 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.


Alliance NCORP Research Base

Buckner, J. C., Paskett, E. D. & Paskett, E. D.

National Institutes of Health


Project: Research project


    Buckner, J. C., Moertel, C. G., Moertel, C. G., Pearson, J., Roche, P., Quella, S., O'Fallon, J., Brindle, J., Itzkowitz, F., Jett, J., Goldberg, R., Steiner, S., Hatfield, A., Weiland, T., O'Connell, M. & Moertel, C. G.


    Project: Research project

    Research Output

    Arti Hurria, M.D. A tribute to her shining legacy in the Alliance for Clinical Trials in Oncology

    On behalf of the Alliance Cancer in the Older Adult Committee, Mar 2020, In : Journal of Geriatric Oncology. 11, 2, p. 179-183 5 p.

    Research output: Contribution to journalShort survey

    Final report from Intergroup NCCTG 86-72-51 (Alliance): A phase III randomized clinical trial of high-dose versus low-dose radiation for adult low-grade glioma

    Breen, W. G., Anderson, S. K., Carrero, X. W., Brown, P. D., Ballman, K. V., O'Neill, B. P., Curran, W. J., Abrams, R. A., Laack, N. N., Levitt, R., Galanis, E., Buckner, J. C. & Shaw, E. G., Jun 9 2020, In : Neuro-oncology. 22, 6, p. 830-837 8 p.

    Research output: Contribution to journalArticle

    Open Access
  • 1 Scopus citations

    Further understanding of glioma mechanisms of pathogenesis: implications for therapeutic development

    Ruff, M., Kizilbash, S. & Buckner, J., May 3 2020, In : Expert review of anticancer therapy. 20, 5, p. 355-363 9 p.

    Research output: Contribution to journalReview article

  • Optimizing Whole Brain Radiation Therapy Dose and Fractionation: Results From a Prospective Phase 3 Trial (NCCTG N107C [Alliance]/CEC.3)

    Trifiletti, D. M., Ballman, K. V., Brown, P. D., Anderson, S. K., Carrero, X. W., Cerhan, J. H., Whitton, A. C., Greenspoon, J., Parney, I. F., Laack, N. N., Ashman, J. B., Bahary, J. P., Hadjipanayis, C. G., Urbanic, J. J., Barker, F. G., Farace, E., Khuntia, D., Giannini, C., Buckner, J. C., Galanis, E. & 1 others, Roberge, D., Feb 1 2020, In : International Journal of Radiation Oncology Biology Physics. 106, 2, p. 255-260 6 p.

    Research output: Contribution to journalArticle

  • 2 Scopus citations

    A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872

    Galanis, E., Anderson, S. K., Twohy, E. L., Carrero, X. W., Dixon, J. G., Tran, D. D., Jeyapalan, S. A., Anderson, D. M., Kaufmann, T. J., Feathers, R. W., Giannini, C., Buckner, J. C., Anastasiadis, P. Z. & Schiff, D., Nov 1 2019, In : Cancer. 125, 21, p. 3790-3800 11 p.

    Research output: Contribution to journalArticle

  • 4 Scopus citations